Conservative as it should be for a 12 month target.
Long term one needs to calculate the value of 15%+ royalties earned in a $3+B market without a viable competing drug for 10 years.
i.e. $450,000+ per annum.
Hell, be conservative and assume all the milestone payments only cover off all of the costs of commercialization and ongoing ops.
$4.5B plus in royalties.
Big numbers.
- Forums
- ASX - By Stock
- DXB
- $2
$2, page-27
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
55.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $302.6M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 135456 | 57.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
55.0¢ | 13200 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 135456 | 0.575 |
2 | 58913 | 0.570 |
1 | 45213 | 0.565 |
1 | 10000 | 0.560 |
1 | 10000 | 0.555 |
Price($) | Vol. | No. |
---|---|---|
0.550 | 13200 | 2 |
0.560 | 19000 | 2 |
0.565 | 30222 | 3 |
0.570 | 70278 | 2 |
0.575 | 131479 | 6 |
Last trade - 09.44am 23/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
Day chart unavailable